Inventiva (NASDAQ:IVA) Shares Gap Up – What’s Next?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) shares gapped up before the market opened on Wednesday . The stock had previously closed at $4.69, but opened at $4.87. Inventiva shares last traded at $4.7950, with a volume of 104,611 shares trading hands.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research note on Friday, July 17th. Cantor Fitzgerald began coverage on shares of Inventiva in a report on Friday, July 17th. They issued an “overweight” rating for the company. Three analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $15.38.

Inventiva Trading Up 1.7%

The company has a 50 day moving average of $4.36 and a 200-day moving average of $5.08.

Institutional Trading of Inventiva

Several hedge funds have recently made changes to their positions in IVA. Seven Fleet Capital Management LP purchased a new position in shares of Inventiva in the first quarter valued at approximately $1,111,000. Virtu Financial LLC purchased a new stake in Inventiva during the 4th quarter worth approximately $60,000. ADAR1 Capital Management LLC acquired a new stake in Inventiva during the 4th quarter worth approximately $12,601,000. XTX Topco Ltd acquired a new stake in Inventiva during the 4th quarter worth approximately $84,000. Finally, Yu Fan purchased a new position in Inventiva in the 4th quarter valued at approximately $6,975,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.